Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP759642.RAYEBQiaXQpMjw826D7YzQvL2avwM27J5eB8BNpN1eb6U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP759642.RAYEBQiaXQpMjw826D7YzQvL2avwM27J5eB8BNpN1eb6U130_assertion type Assertion NP759642.RAYEBQiaXQpMjw826D7YzQvL2avwM27J5eB8BNpN1eb6U130_head.
- NP759642.RAYEBQiaXQpMjw826D7YzQvL2avwM27J5eB8BNpN1eb6U130_assertion description "[Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP759642.RAYEBQiaXQpMjw826D7YzQvL2avwM27J5eB8BNpN1eb6U130_provenance.
- NP759642.RAYEBQiaXQpMjw826D7YzQvL2avwM27J5eB8BNpN1eb6U130_assertion evidence source_evidence_literature NP759642.RAYEBQiaXQpMjw826D7YzQvL2avwM27J5eB8BNpN1eb6U130_provenance.
- NP759642.RAYEBQiaXQpMjw826D7YzQvL2avwM27J5eB8BNpN1eb6U130_assertion SIO_000772 15946589 NP759642.RAYEBQiaXQpMjw826D7YzQvL2avwM27J5eB8BNpN1eb6U130_provenance.
- NP759642.RAYEBQiaXQpMjw826D7YzQvL2avwM27J5eB8BNpN1eb6U130_assertion wasDerivedFrom befree-20140225 NP759642.RAYEBQiaXQpMjw826D7YzQvL2avwM27J5eB8BNpN1eb6U130_provenance.
- NP759642.RAYEBQiaXQpMjw826D7YzQvL2avwM27J5eB8BNpN1eb6U130_assertion wasGeneratedBy ECO_0000203 NP759642.RAYEBQiaXQpMjw826D7YzQvL2avwM27J5eB8BNpN1eb6U130_provenance.